Details for Patent: 8,653,094

Which drugs does patent 8,653,094 protect, and when does it expire?

Patent 8,653,094 protects XERMELO and is included in one NDA.

This patent has twenty-nine patent family members in twenty-five countries.

Summary for Patent: 8,653,094

Title:	Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phen- yl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use
Abstract:	Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phen- yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate and salts thereof are disclosed.
Inventor(s):	Bednarz; Mark S. (Yardley, PA), De Paul; Susan (Zurich, CH), Kanamarlapudi; Ramanaiah C. (Bridgewater, NJ), Perlberg; Anett (Gunzgen, CH), Zhang; Haiming (San Mateo, CA)
Assignee:	Lexicon Pharmaceuticals, Inc. (The Woodlands, TX)
Application Number:	13/486,103
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,653,094

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Tersera	XERMELO	telotristat etiprate	TABLET;ORAL	208794-001	Feb 28, 2017		RX	Yes	Yes						THE TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY

International Family Members for US Patent 8,653,094

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	068558
Australia	2008304439
Brazil	PI0817270
Canada	2700835
Chile	2008002880
China	101809018